High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance

被引:0
|
作者
H A Cocker
S M Hobbs
N Tiffin
K Pritchard-Jones
C R Pinkerton
L R Kelland
机构
[1] CRC Centre for Cancer Therapeutics,
[2] The Institute of Cancer Research,undefined
[3] Section of Paediatrics,undefined
[4] The Institute of Cancer Research/Royal Marsden NHS Trust,undefined
来源
British Journal of Cancer | 2001年 / 85卷
关键词
mdm2; resistance; P-glycoprotein; rhabdomyosarcoma;
D O I
暂无
中图分类号
学科分类号
摘要
The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas. © 2001 Cancer Research Campaign http://www.bjcancer.com
引用
下载
收藏
页码:1746 / 1752
页数:6
相关论文
共 50 条
  • [21] MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset
    Hamid, Sharifah
    Yang, Yi-Hsin
    Peng, Karen Ng Lee
    Ismail, Siti Mazlipah
    Zain, Rosnah Binti
    Lim, Kue Peng
    Mustafa, Wan Mahadzir Wan
    Abraham, Mannil Thomas
    Teo, Soo-Hwang
    Cheong, Sok Ching
    ORAL ONCOLOGY, 2009, 45 (06) : 496 - 500
  • [22] Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas
    Mariatos, G
    Gorgoulis, VG
    Kotsinas, A
    Zacharatos, P
    Kokotas, S
    Yannoukakos, D
    Kittas, C
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 456 (1-2) : 59 - 63
  • [23] Stress-Induced Isoforms of MDM2 and MDM4 Correlate with High-Grade Disease and an Altered Splicing Network in Pediatric Rhabdomyosarcoma
    Jacob, Aishwarya G.
    O'Brien, Dennis
    Singh, Ravi K.
    Comiskey, Daniel F., Jr.
    Littleton, Robert M.
    Mohammad, Fuad
    Gladman, Jordan T.
    Widmann, Maria C.
    Jeyaraj, Selvi C.
    Bolinger, Cheryl
    Anderson, James R.
    Barkauskas, Donald A.
    Boris-Lawrie, Kathleen
    Chandler, Dawn S.
    NEOPLASIA, 2013, 15 (09): : 1049 - 1063
  • [24] Significance of MDM2-309 Polymorphisms and Induced Corresponding Plasma MDM2 Levels in Susceptibility to Laryngeal Squamous Cell Carcinoma
    Zhou, Jian
    Liu, Fei
    Zhang, Duo
    Chen, Bin
    Li, Qing
    Zhou, Lin
    Lu, Li-Ming
    Tao, Lei
    DNA AND CELL BIOLOGY, 2014, 33 (02) : 88 - 94
  • [25] Imaging Flow-Cytometer Based Detection of ALK and MDM2 Amplification in Neuroblastoma Cell Lines
    Wright, J. H.
    Humphreys, A.
    Gabriel, A. S.
    Bown, N.
    Chen, L.
    Jamieson, D.
    Tweddle, D. A.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S195 - S195
  • [26] Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
    Wang, Hui Qin
    Halilovic, Ensar
    Li, Xiaoyan
    Liang, Jinsheng
    Cao, Yichen
    Rakiec, Daniel P.
    Ruddy, David A.
    Jeay, Sebastien
    Wuerthner, Jens U.
    Timple, Noelito
    Kasibhatla, Shailaja
    Li, Nanxin
    Williams, Juliet A.
    Sellers, William R.
    Huang, Alan
    Li, Fang
    ELIFE, 2017, 6
  • [27] THE MDM2 ONCOGENE OVEREXPRESSION IN CHRONIC LYMPHOCYTIC-LEUKEMIA AND LOW-GRADE LYMPHOMA OF B-CELL ORIGIN
    WATANABE, T
    HOTTA, T
    ICHIKAWA, A
    KINOSHITA, T
    NAGAI, H
    UCHIDA, T
    MURATE, T
    SAITO, H
    BLOOD, 1994, 84 (09) : 3158 - 3165
  • [28] MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
    Ohnstad, Hege O.
    Paulsen, Erik B.
    Noordhuis, Paul
    Berg, Marianne
    Lothe, Ragnhild A.
    Vassilev, Lyubomir T.
    Myklebost, Ola
    BMC CANCER, 2011, 11
  • [29] MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
    Hege O Ohnstad
    Erik B Paulsen
    Paul Noordhuis
    Marianne Berg
    Ragnhild A Lothe
    Lyubomir T Vassilev
    Ola Myklebost
    BMC Cancer, 11
  • [30] MDM2-Mediated Resistance of Lung Cancer Cell Lines to Genotoxic Drugs
    Fedorova, Olga A.
    Shuvalov, Oleg Y.
    Daks, Alexandra A.
    Petukhov, Alexey V.
    Vasileva, Elena A.
    Barlev, Nikolai A.
    CELL DEATH DISCOVERY, 2020, 6 (01)